Genome Editing Market Size

Genome Editing Market size was valued at USD 9.47 billion in 2024 and is expected to exceed USD 64.48 billion by the end of 2037, registering over 15.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of genome editing is evaluated at USD 10.67 billion. The market's growth is primarily due to the high prevalence of cancer around the globe. In 2020, the World Health Organization reported that approximately 10 million people succumbed to cancer worldwide. The most common types of cancer that caused fatalities were lung cancer, which accounted for 1.8 million deaths, colon and rectal cancer with 916,000 deaths, liver cancer with 830,000 deaths, stomach cancer with 769,000 deaths, and breast cancer with 685,000 deaths. Furthermore, diseases like human papillomavirus (HPV) and hepatitis have been found to cause about 30% of cancer cases in low- and middle-income countries.

The market is growing due to advancements in gene editing tools, government funding, and an increase in genomics projects. The rise in cancer and genetic diseases and the development of CRISPR-based diagnostic tools for COVID-19 are also contributing. CRISPR-Cas9 dominates with 65% revenue share, expected to reach 70% by 2025. High device costs and ethical concerns hinder growth, but emerging markets and drug discovery opportunities hold promise.